DOCSLIB.ORG

Overview: Malaysian Healthcare Biotechnology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overview: Malaysian Healthcare Biotechnology Overview: Malaysian Healthcare Biotechnology The Malaysian Healthcare Biotechnology Sector A Frost & Sullivan Whitepaper 2009 1 Contents Please note; all data included in this paper is from published sources or Frost & 04 •Introduction Sullivan’s proprietary information, or from industry participants. Where currencies are mentioned, the conversion of Malaysian Ringgit to US Dollar 05 •Goals and Strategies for the Sector uses the following exchange rate: RM 3.6 = US$1.0 Malaysian Biotechnology Policy Disclaimer 9th Malaysia Plan Information, opinions or recommendations provided by Frost & Sullivan are presented solely for informational purposes. The information used and statements of fact made 08 •Malaysian Healthcare: Over the years and today have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy of such statements. The information presented 10 •Healthcare Biotechnology Focus Areas and the opinions expressed are subject to change without notice. Frost & Sullivan Focus Sector Overview: CMO takes no responsibility for any incorrect information supplied to us by published Focus Sector Overview: CRO sources or industry participants; however all care is taken to verify data. Quantitative Focus Sector Overview: Biopharmaceuticals/Biogenerics market information is subject to fluctuation. In no event will Frost & Sullivan or Focus Sector Overview: Medical Devices & Diagnostics employees thereof be liable for any decision made or action taken in reliance on the Focus Sector Overview: Therapeutics information in this report or for any consequential, special or similar damages, even if Focus Sector Overview: Drug discovery and Drug Delivery advised of the possibility of such damages. About Frost & Sullivan 17 •Key Success Factors Frost & Sullivan, a global growth consulting company, has been partnering with Biodiversity: Healthcare/Therapeutics clients to support the development of innovative strategies for more than 45 years. The Designated Economic Corridors company's industry expertise integrates growth consulting, growth partnership BioNexus services and corporate management training to identify and develop opportunities. Government Incentives Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, Human Capital emerging companies, and the investment community, by providing comprehensive Intellectual Property Right Protection industry coverage that reflects a unique global perspective and combines ongoing Funding analysis of markets, technologies, econometrics and demographics. 24 •Conclusion For more information, visit www.frost.com 2 Contents Please note; all data included in this paper is from published sources or Frost & 04 •Introduction Sullivan’s proprietary information, or from industry participants. Where currencies are mentioned, the conversion of Malaysian Ringgit to US Dollar 05 •Goals and Strategies for the Sector uses the following exchange rate: RM 3.6 = US$1.0 Malaysian Biotechnology Policy Disclaimer 9th Malaysia Plan Information, opinions or recommendations provided by Frost & Sullivan are presented solely for informational purposes. The information used and statements of fact made 08 •Malaysian Healthcare: Over the years and today have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy of such statements. The information presented 10 •Healthcare Biotechnology Focus Areas and the opinions expressed are subject to change without notice. Frost & Sullivan Focus Sector Overview: CMO takes no responsibility for any incorrect information supplied to us by published Focus Sector Overview: CRO sources or industry participants; however all care is taken to verify data. Quantitative Focus Sector Overview: Biopharmaceuticals/Biogenerics market information is subject to fluctuation. In no event will Frost & Sullivan or Focus Sector Overview: Medical Devices & Diagnostics employees thereof be liable for any decision made or action taken in reliance on the Focus Sector Overview: Therapeutics information in this report or for any consequential, special or similar damages, even if Focus Sector Overview: Drug discovery and Drug Delivery advised of the possibility of such damages. About Frost & Sullivan 17 •Key Success Factors Frost & Sullivan, a global growth consulting company, has been partnering with Biodiversity: Healthcare/Therapeutics clients to support the development of innovative strategies for more than 45 years. The Designated Economic Corridors company's industry expertise integrates growth consulting, growth partnership BioNexus services and corporate management training to identify and develop opportunities. Government Incentives Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, Human Capital emerging companies, and the investment community, by providing comprehensive Intellectual Property Right Protection industry coverage that reflects a unique global perspective and combines ongoing Funding analysis of markets, technologies, econometrics and demographics. 24 •Conclusion For more information, visit www.frost.com 3 Goals and Strategies Introduction for the Sector The healthcare biotechnology industry is undoubtedly a strategic investment opportunity, both from an Malaysia has identified biotechnology as one of the new engines of growth for the national economy and it is economic as well as a social stand-point. Thanks to cutting-edge research, biotechnology companies have expected that the sector will generate US$75 billion (RM270 billion) in revenues by 2020. The country has a contributed a portfolio of products to diverse industries ranging from human and animal health to protection of rich biodiversity and cost-competitive skilled labour markets, as well as good transportation networks, ICT the environment and in the food-processing industries. Globally, there are about 4,000 small- and infrastructure and strong capabilities in R&D. These combined characteristics make Malaysia an attractive medium-scale enterprises belonging to the biotechnology fraternity, and they are involved in continuous potential destination for foreign biotechnology companies and investors interested in the healthcare research. Biotechnology has created more than 200 new therapies and vaccines, including products to treat biotechnology sector. cancer, diabetes, HIV/ AIDS and autoimmune disorders. As traditional pharmaceutical industry pipelines dry up, the industry has started looking towards biotechnology to fill this gap. The Malaysian Biotechnology Policy While the market capital of the top 5 US pharma companies has fallen approximately 20% in the last 5 years, the biotech market capital has seen an 18% gain over the same period. The Malaysian Government has identified the biotechnology sector as one of the key strategic sectors that will support the growth of the Malaysian economy. It is anticipated that growth in the sector will be supported by Top Five US Pharma* vs. Total Biotech Market Cap leveraging on the strength of the country’s diverse natural resources and cost effective human capital talent Market Value of selected pool. The Government has identified the need to create a strong supporting framework to facilitate the long $800 Big Pharma acquisitions of public Biotechs term growth of the sector. In 2005 the Malaysian government enacted the Malaysia Biotechnology Policy to (2005-2009) Despite a general perception and a consensus on the $700 achieve this goal. The policy detailed nine focus areas deemed critical to creation of a sustained biotechnology Top Five US Pharma* = $284 Billion positive outlook for the healthcare biotechnology ($ Billion) sector, one of which is to support the growth of the industrial biotechnology sector. $600 industry, some of the constraints that plague the $168 Billion $500 progress of the biotechnology industry are highly The Malaysian Biotechnology Policy detailed a series of aggressive development goals. The biotechnology industry $400 undervalued stocks of these biotech companies, $162 Billion is expected to contribute approximately 2.5 % of national GDP by 2010, 4.0% by 2015 and 5.0% by 2020. insufficient funding, inexperienced management and $300 Furthermore, it is estimated that the industry will create 280,000 new jobs – both directly and indirectly – by 2020. a sound conceptualization of the business model. $200 Total Biotech Market Cap = $290 Billion Investments in biotechnology are considered risky, Total Market Value $100 and investors are increasingly reluctant to invest in The Nine Thrusts of the National Biotechnology Policy $0 biotechnology companies. The number of IPOs 1 Agricultural Biotechnology Transform and enhance the value creation of the agricultural sector 2001 2002 2003 2004 2005 2006 2007 2008 2009 within the biotechnology industry has declined as through biotechnology. *Pfizer, Merck, Lilly, Wyeth, and Schering-Plough well, reflecting investors’ concern on the average 2 Healthcare Biotechnology Capitalise on the country's biodiversity for commercialising the Source: Capital IQ, Windhover, Burrill Analysis length of time taken to achieve a return on investment. discoveries of health related natural products and bio-generic drugs. In the Asian region, other than Japan and Australia, countries like China, India, Korea and Singapore are 3 Industrial Biotechnology Leverage on the country's strong manufacturing sector to increase emerging as key destinations for the healthcare biotechnology
Load more

Recommended publications
  • Pharmaceutical Sector
    MARKET REVIEW ON PRIORITY SECTOR UNDER COMPETITION ACT 2010 PHARMACEUTICAL SECTOR Malaysia Competition Commission (MyCC) 27 December 2017 TABLE OF CONTENTS Executive Summary 2 List of Abbreviations 7 Glossary 9 Introduction 16 Methodology and Limitations 18 Policy Context for the Review 24 PART ONE: OVERVIEW OF MALAYSIA’s PhARMACEUTICAL SECtor Chapter 1: Overall Growth of the Healthcare and Pharmaceutical Sectors 28 Chapter 2: Market Structure and Supply Chain 41 Chapter 3: Market Share and Market Concentration 69 Chapter 4: Market Dominance and Impact on Availability, Affordability and Accessibility of Medicines 93 PART TWO: COMPETITION CONCERNS IN THE PHARMACEUTICAL SECtor Chapter 5: Key Existing Laws and Regulations and An Assessment of Impacts 118 Chapter 6: Competition Concerns Among Industry Players 148 Chapter 7: Selected Case Studies on Anti-Competitive Conduct 177 PART THREE: CONCLUSION AND RECOMMENDatIONS Chapter 8: Conclusion and Recommendations 208 APPENDICES Appendix 1: Guiding Questions for Interviews with Industry Players 224 Appendix 2: Malaysian Organization of Pharmaceutical Industries (MOPI) Members 229 Appendix 3: Brief Profiles of Top 6 Malaysian Local/Joint Venture Pharmaceutical Companies 230 Appendix 4: Pharmaceutical Association of Malaysia (PhAMA) Members 232 Appendix 5: Malaysian Association of Pharmaceutical Suppliers (MAPS) Members 233 Appendix 6: Drug Registration Process 234 References 236 EXECUTIVE SUMMARY The aims of Malaysia’s National Medicines Policy are to promote equitable access to, and rational use of, safe, effective and affordable medicines by its population. In order to maximize social welfare, this policy is strengthened by Malaysia’s Competition Act of 2010 and the establishment of the Malaysia Competition Commission (MyCC) to bring about allocation, production and innovation efficiencies.
    [Show full text]
  • Journal Officiel De L'union Européenne 23.9.2003
    450 FR Journal officiel de l'Union européenne 23.9.2003 Appendice A visé au Chapitre 1, point 2, de l'annexe XI (*) Liste, fournie en une seule langue par Malte, des médicaments pour lesquels l'autorisation de mise sur le marché délivrée en vertu du droit maltais avant la date d'adhésion demeurera valable jusqu'à ce qu'elle soit renouvelée conformément à l'acquis ou jusqu'au 31 décembre 2006, si cette dernière date est plus proche. L'inscription d'un médicament sur cette liste ne signifie pas forcément que l'autorisation de mise sur le marché obtenue est conforme à l'acquis. LISTE DES MÉDICAMENTS À INCLURE DANS L'ARRANGEMENT NÉGOCIÉ DANS LE CADRE DU CHAPITRE I Trade Name Dosage Form Dose MA Holder Country 0.45% SODIUM CHLORIDE IN 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE AG 0.45% SODIUM CHLORIDE SOLUTION FOR 0.45% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.45% SODIUM CHLORIDE SOLUTION FOR IV 4.5MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION, USP INJECTION AMERICA 0.9% SOD. CHLORIDE AND 5% SOLUTION FOR N/A BAXTER HEALTHCARE UNITED KINGDOM GLUCOSE INJECTION LIMITED 0.9% SODIUM CHLORIDE AND 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE IV INF AG 0.9% SODIUM CHLORIDE SOLUTION FOR INJ 9MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 9MG/ML ABBOTT LABORATORIES UNITED STATES OF IRRIGATION IRRIGATION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF IRRIGATION USP IRRIGATION AMERICA 0.9% W/V SODIUM CHLORIDE SOLUTION FOR 0.9% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP INJECTION AG 0.9% W/V SODIUM CHLORIDE IRRIGATION SOLUTION 0.9% W/V B.BRAUN MELSUNGEN GERMANY IRRIGATION SOL.
    [Show full text]
  • Medicine Procurement Prices and Processesin the United Nations Relief
    medicine procurement prices and processes in the united nations relief and works agency for palestine refugees in the near east (UNRWA) december 2011 "© United Nations Relief and Works Agency for Palestine Refugees in the Near East, 2012. All rights reserved. The views expressed in this report are those of the author(s) and do not necessarily reflect the views of UNRWA. UNRWA does not endorse or recommend specific medicines, companies or products of manufacturers, whether or not mentioned in this report. UNRWA does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use." 2 Table of Contents Abbreviations .............................................................................................................................. 5 Foreword .................................................................................................................................... 6 Executive Summary ..................................................................................................................... 7 1. Introduction ......................................................................................................................... 8 2. Objectives .......................................................................................................................... 10 3. Methodology ..................................................................................................................... 11 3.1 Data collection
    [Show full text]
  • New Capacity with Higher Standards
    Continuous Innovation & Quality HOVID BERHAD (58476-A) New Capacity with Higher Standards Annual Report 2016 Annual Report 2016 CONTENTS 2 NOTICE OF ANNUAL GENERAL MEETING 12 CORPORATE INFORMATION 13 CORPORATE STRUCTURE 14 DIRECTORS’ PROFILE 16 KEY MANAGEMENT PROFILE 18 CHAIRMAN’S STATEMENT 22 FINANCIAL HIGHLIGHTS 23 STATEMENT ON CORPORATE GOVERNANCE 33 STATEMENT ON RISK MANAGEMENT AND INTERNAL CONTROL 35 AUDIT COMMITTEE REPORT 37 FINANCIAL STATEMENTS 112 LIST OF PROPERTIES 116 ANALYSIS OF SHAREHOLDINGS 118 ANALYSIS OF WARRANT HOLDINGS 120 SHARE BUY-BACK STATEMENT ENCLOSED PROXY FORM 2 HOVID BERHAD (58476-A) ANNUAL REPORT 2016 NOTICE OF ANNUAL GENERAL MEETING NOTICE IS HEREBY GIVEN that the Thirty-sixth (36th) Annual General Meeting (“AGM”) of Hovid Berhad (“Hovid” or “the Company”) will be held at Conference 1, Level 2, Weil Hotel, 292, Jalan Sultan Idris Shah, 30000 Ipoh, Perak Darul Ridzuan on Tuesday, 22 November 2016 at 10.30 a.m. for the following purposes:- AGENDA As Ordinary Business:- 1. To receive the Audited Financial Statements for the financial year ended 30 June 2016 Please refer to together with the Reports of the Directors and Independent Auditors thereon. Explanatory Note 1 2. To approve the payment of Directors’ fees of RM402,000 for the financial year ended 30 June Ordinary Resolution 1 2016. 3. To re-elect the following Directors who retire pursuant to Article 83 of the Company’s Articles of Association:- (a) Mr Chiam Tau Meng Ordinary Resolution 2 (b) Mr Goh Tian Hock Ordinary Resolution 3 4. To re-appoint Messrs SJ Grant Thornton as Auditors of the Company for the ensuing year Ordinary Resolution 4 and to authorise the Directors to fix their remuneration.
    [Show full text]
  • African Journal of Pharmacy and Pharmacology
    African Journal of Pharmacy and Pharmacology Volume 7 Number 23 22 June, 2013 ISSN 1996- 0816 ABOUT AJPP The African Journal of Pharmacy and Pharmacology (AJPP) is published weekly (one volume per year) by Academic Journals. African Journal of Pharmacy and Pharmacology (AJPP) is an open access journal that provides rapid publication (weekly) of articles in all areas of Pharmaceutical Science such as Pharmaceutical Microbiology, Pharmaceutical Raw Material Science, Formulations, Molecular modeling, Health sector Reforms, Drug Delivery, Pharmacokinetics and Pharmacodynamics, Pharmacognosy, Social and Administrative Pharmacy, Pharmaceutics and Pharmaceutical Microbiology, Herbal Medicines research, Pharmaceutical Raw Materials development/utilization, Novel drug delivery systems, Polymer/Cosmetic Science, Food/Drug Interaction, Herbal drugs evaluation, Physical Pharmaceutics, Medication management, Cosmetic Science, pharmaceuticals, pharmacology, pharmaceutical research etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in AJPP are peer-reviewed. Submission of Manuscript Submit manuscripts as e-mail attachment to the Editorial Office at: [email protected]. A manuscript number will be mailed to the corresponding author shortly after submission. The African Journal of Pharmacy and Pharmacology will only accept manuscripts submitted as e-mail attachments. Please read the Instructions for Authors before submitting your manuscript. The manuscript files should be given the last name of the first author. Editors Sharmilah Pamela Seetulsingh- Goorah Dr.B.RAVISHANKAR Associate Professor, Director and Professor of Experimental Medicine Department of Health Sciences SDM Centre for Ayurveda and Allied Sciences, Faculty of Science, SDM College of Ayurveda Campus, University of Mauritius, Kuthpady, Udupi- 574118 Reduit, Karnataka (INDIA) Mauritius Dr.
    [Show full text]